Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Khyber Pakhtunkhwa
-
Abbottābād, Khyber Pakhtunkhwa, Pakistan, 22010
- CMH Abbottabad
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All the patients above 18 years of age
- Diagnosed with pityriasis versicolor
Exclusion Criteria:
- Those patients who had received any antifungal treatment during last 1 month
- pregnancy
- lactation
- history of renal disease hepatic disease or malignancy
- history of hepatic disease
- history of malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Group A Fluconazole
Oral fluconazole (400 mg stat) given to patients.
|
400 mg stat.
Follow up at 4 weeks
Other Names:
1000 mg stat.
Follow up at 4 weeks
Other Names:
|
|
Active Comparator: Group B Itraconazole
Oral Itraconazole (1000 mg stat) given to patients.
|
400 mg stat.
Follow up at 4 weeks
Other Names:
1000 mg stat.
Follow up at 4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Improvement Resolution of symptoms
Time Frame: 4 weeks
|
Efficacy of treatment was assessed by mycological test by making KOH mount at start of treatment and than at follow up at 4 weeks
|
4 weeks
|
|
Efficacy of treatment through KOH mount
Time Frame: 4 weeks
|
Efficacy of treatment was assessed by mycological test by making KOH mount at start of treatment and than at follow up at 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Skin Diseases, Papulosquamous
- Mycoses
- Dermatomycoses
- Tinea Versicolor
- Pityriasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Itraconazole
- Fluconazole
Other Study ID Numbers
Other Study ID Numbers
- CMHAbbottabad1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.